title: Ð£ÑÐ¾Ð²ÐµÐ½Ñ ÐÐÐ-Ð¼ÐµÑÐ¸Ð»ÑÑÐ°Ð½ÑÑÐµÑÐ°Ð·Ñ 1 (DNMT1) Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¿ÑÐ¸ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
title: Ð²ÑÐ¿ÑÑÐºÐ½Ð°Ñ ÐºÐ²Ð°Ð»Ð¸ÑÐ¸ÐºÐ°ÑÐ¸Ð¾Ð½Ð½Ð°Ñ ÑÐ°Ð±Ð¾ÑÐ° Ð±Ð°ÐºÐ°Ð»Ð°Ð²ÑÐ°
titleType: Subtitle
title: DNA methyltransferase 1 (DNMT1) protein level in CD45 + peripheral blood cells in Parkinson's disease
Creators: name: ÐÐ°Ð³Ð°ÑÐ¸Ð½Ð°, ÐÐ°Ð²Ð»Ð°
Publisher: name: Ð¡Ð°Ð½ÐºÑ-ÐÐµÑÐµÑÐ±ÑÑÐ³ÑÐºÐ¸Ð¹ Ð¿Ð¾Ð»Ð¸ÑÐµÑÐ½Ð¸ÑÐµÑÐºÐ¸Ð¹ ÑÐ½Ð¸Ð²ÐµÑÑÐ¸ÑÐµÑ ÐÐµÑÑÐ° ÐÐµÐ»Ð¸ÐºÐ¾Ð³Ð¾
Year: 2019
Subjects: Ð±Ð¾Ð»ÐµÐ·Ð½Ñ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð°
Ð´Ð¾ÑÐ°Ð¼Ð¸Ð½
Ð´Ð¾ÑÐ°Ð¼Ð¸Ð½ÐµÑÐ³Ð¸ÑÐµÑÐºÐ¸Ðµ Ð½ÐµÐ¹ÑÐ¾Ð½Ñ
ÑÐµÑÐ½Ð°Ñ ÑÑÐ±ÑÑÐ°Ð½ÑÐ¸Ñ
Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½
SNCA
Ð»Ð¸Ð¼ÑÐ¾ÑÐ¸ÑÑ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸
ÐÐÐ-Ð¼ÐµÑÐ¸Ð»ÑÑÐ°Ð½ÑÑÐµÑÐ°Ð·Ñ
DNMT1
Parkinson's disease
dopamine
dopaminergic neurons
substantia nigra
alpha-sinuclein
peripherial blood lymphocytes
DNA-methyltransferases

description: ÐÑÐµÐ´Ð¿Ð¾Ð»Ð°Ð³Ð°ÐµÑÑÑ, ÑÑÐ¾ Ð½ÐµÐ¹ÑÐ¾Ð´ÐµÐ³ÐµÐ½ÐµÑÐ°ÑÐ¸Ñ Ð¿ÑÐ¸ Ð±Ð¾Ð»ÐµÐ·Ð½Ð¸ ÐÐ°ÑÐºÐ¸Ð½ÑÐ¾Ð½Ð° Ð°ÑÑÐ¾ÑÐ¸Ð¸ÑÐ¾Ð²Ð°Ð½Ð° Ñ Ð³Ð¸Ð±ÐµÐ»ÑÑ Ð´Ð¾ÑÐ°Ð¼Ð¸Ð½ÐµÑÐ³Ð¸ÑÐµÑÐºÐ¸Ñ Ð½ÐµÐ¹ÑÐ¾Ð½Ð¾Ð², Ð¾Ð±ÑÑÐ»Ð¾Ð²Ð»ÐµÐ½Ð½Ð¾Ð¹ Ð½Ð°ÐºÐ¾Ð¿Ð»ÐµÐ½Ð¸ÐµÐ¼ Ð¾Ð»Ð¸Ð³Ð¾Ð¼ÐµÑÐ½ÑÑ ÑÐ¾ÑÐ¼ Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½Ð° Ð² Ð½Ð¸Ñ. ÐÐ¾ÐºÐ°Ð·Ð°Ð½Ð¾, ÑÑÐ¾ Ð½Ð° Ð¿ÑÐ¾ÑÐµÑÑ Ð¾Ð»Ð¸Ð³Ð¾Ð¼ÐµÑÐ¸Ð·Ð°ÑÐ¸Ð¸ Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½Ð° Ð² ÐºÐ»ÐµÑÐºÐµ Ð¼Ð¾Ð¶ÐµÑ Ð²Ð»Ð¸ÑÑÑ Ð´Ð¾ÑÐ°Ð¼Ð¸Ð½. Ð ÑÐ¾ Ð¶Ðµ Ð²ÑÐµÐ¼Ñ Ð¾Ð»Ð¸Ð³Ð¾Ð¼ÐµÑÐ½ÑÐ¹ Ð°Ð»ÑÑÐ°-ÑÐ¸Ð½ÑÐºÐ»ÐµÐ¸Ð½ ÑÐ¿Ð¾ÑÐ¾Ð±ÑÑÐ²ÑÐµÑ Ð¿Ð¾ÑÐµÑÐµ ÑÐ´ÐµÑÐ½Ð¾Ð¹ Ð»Ð¾ÐºÐ°Ð»Ð¸Ð·Ð°ÑÐ¸Ð¸ ÐºÐ»ÑÑÐµÐ²Ð¾Ð³Ð¾ ÑÐµÑÐ¼ÐµÐ½ÑÐ° Ð² Ð¿ÑÐ¾ÑÐµÑÑÐµ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ Ð³ÐµÐ½Ð¾Ð¼Ð½Ð¾Ð¹ ÐÐÐ, ÐÐÐ-Ð¼ÐµÑÐ¸Ð»ÑÑÐ°Ð½ÑÑÐµÑÐ°Ð·Ñ 1 (DNMT1), Ð¿ÑÐ¸Ð²Ð¾Ð´Ñ Ðº ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ñ ÑÑÐµÐ¿ÐµÐ½Ð¸ Ð¼ÐµÑÐ¸Ð»Ð¸ÑÐ¾Ð²Ð°Ð½Ð¸Ñ ÑÐµÐ³ÑÐ»ÑÑÐ¾ÑÐ½Ð¾Ð¹ Ð¾Ð±Ð»Ð°ÑÑÐ¸ Ð³ÐµÐ½Ð° SNCA. Ð ÑÐ²ÑÐ·Ð¸ Ñ ÑÑÐ¸Ð¼ ÑÐµÐ»ÑÑ Ð½Ð°ÑÑÐ¾ÑÑÐµÐ¹ ÑÐ°Ð±Ð¾ÑÑ Ð±ÑÐ»Ð¾ Ð¸ÑÑÐ»ÐµÐ´Ð¾Ð²Ð°Ð½Ð¸Ðµ ÑÑÐ¾Ð²Ð½Ñ ÐÐÐ-Ð¼ÐµÑÐ¸Ð»ÑÑÐ°Ð½ÑÑÐµÑÐ°Ð·Ñ 1 Ð² CD45+ ÐºÐ»ÐµÑÐºÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸, Ð° ÑÐ°ÐºÐ¶Ðµ Ð²Ð»Ð¸ÑÐ½Ð¸ÐµinvitroÑÐºÐ·Ð¾Ð³ÐµÐ½Ð½Ð¾Ð³Ð¾ ÐÐ Ð½Ð° ÑÑÐ¾Ð²ÐµÐ½Ñ DNMT1 Ð² Ð»Ð¸Ð¼ÑÐ¾ÑÐ¸ÑÐ°Ñ Ð¿ÐµÑÐ¸ÑÐµÑÐ¸ÑÐµÑÐºÐ¾Ð¹ ÐºÑÐ¾Ð²Ð¸ Ð¿ÑÐ¸ ÐÐ.
ÐÐ°Ð¼Ð¸ Ð²Ð¿ÐµÑÐ²ÑÐµ Ð±ÑÐ»Ð¾ Ð¿Ð¾ÐºÐ°Ð·Ð°Ð½Ð¾ ÑÐ½Ð¸Ð¶ÐµÐ½Ð¸Ðµ ÑÑÐ¾Ð²Ð½Ñ Ð±ÐµÐ»ÐºÐ° DNMT1 Ð² ÐÐÐ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ Ð¿Ð¾ ÑÑÐ°Ð²Ð½ÐµÐ½Ð¸Ñ Ñ ÐºÐ¾Ð½ÑÑÐ¾Ð»ÐµÐ¼. ÐÐ¾ÐºÐ°Ð·Ð°Ð½Ð¾ Ð¾ÑÑÑÑÑÑÐ²Ð¸Ðµ Ð²Ð»Ð¸ÑÐ½Ð¸Ñ Ð´Ð¾ÑÐ°Ð¼Ð¸Ð½Ð° Ð½Ð° ÑÑÐ¾Ð²ÐµÐ½Ñ DNMT1 Ð² ÐÐÐ Ð¿Ð°ÑÐ¸ÐµÐ½ÑÐ¾Ð² Ñ ÐÐ Ð¸ Ð¸Ð½Ð´Ð¸Ð²Ð¸Ð´ÑÑÐ¼Ð¾Ð² ÐºÐ¾Ð½ÑÑÐ¾Ð»Ñ Ð² ÑÐ´ÐµÑÐ½Ð¾Ð¹ Ð¸ ÑÐ¸ÑÐ¾Ð·Ð¾Ð»ÑÐ½Ð¾Ð¹ Ð±ÐµÐ»ÐºÐ¾Ð²ÑÑ ÑÑÐ°ÐºÑÐ¸ÑÑ.
Ð¢Ð°ÐºÐ¸Ð¼ Ð¾Ð±ÑÐ°Ð·Ð¾Ð¼, Ð¿Ð¾Ð»ÑÑÐµÐ½Ð½ÑÐµ Ð´Ð°Ð½Ð½ÑÐµ Ð¿Ð¾Ð·Ð²Ð¾Ð»ÑÑÑ Ð¿ÑÐµÐ´Ð»Ð¾Ð¶Ð¸ÑÑ Ð¸ÑÐ¿Ð¾Ð»ÑÐ·Ð¾Ð²Ð°Ð½Ð¸Ðµ ÑÑÐ¾Ð²Ð½Ñ DNMT1 Ð² ÐÐÐ Ð² ÐºÐ°ÑÐµÑÑÐ²Ðµ Ð±Ð¸Ð¾Ð¼Ð°ÑÐºÐµÑÐ° ÑÐ°Ð·Ð²Ð¸ÑÐ¸Ñ ÐÐ.
description: It is assumed that neurodegeneration in Parkinson's disease is associated with the flexibility of dopaminergic neurons, due to the accumulation of oligomeric forms of alpha synuclein in them. It has been shown that dopamine can influence the process of oligomerization of alpha-synuclein in a cell. At the same time, oligomeric alpha synuclein contributes to the localization of a key enzyme in the process of methylation of genomic DNA, DNA methyltransferase 1 (DNMT1), leading to a low degree of methylation of the regulatory region of the SNCA gene. The purpose of this work was to study the level of DNA methyltransferase 1 in CD45 + cells and the affect of exogenous DA at the level of DNMT1 in peripheral blood lymphocytes in PD.
We first showed a decrease in the level of protein DNMT1 in comparison with the control. The absence of dopamine influence on the level of DNMT1 in the PBL of patients with PD and control group individuals in the nuclear and cytosolic protein fractions wasshown.Thus, the data allow us to suggest the use of the DNMT1 level in the diagnostics as a biomarker for the development of PD.